1 of 1
Story summary
- England's NHS will provide Enhertu to about 1,000 women with HER2-low advanced breast cancer after NICE approval.
- NICE approved the drug following a commercial deal with AstraZeneca and Daiichi Sankyo.
- Trials showed Enhertu doubled progression-free survival to 9.9 months and raised overall survival by 6.6 months to 23.4 months.
- NICE can now spend up to £35,000 per patient annually, up from £30,000.